GlassScriptPhysician profile
Stephen S Miller
NPI 1841302288
$4,665.19
in general payments reported to CMS, 2019-2025
44 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $1,391 · 2021: $952 · 2022: $554 · 2023: $63.33 · 2024: $28.02 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $700.96 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $553.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $439.61 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $340.57 | 2019-2022 | |
| Amgen INC. | $319.73 | 2019-2022 | |
| Abbott Laboratories | $290.73 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Genentech USA, INC. | $179.27 | 2019-2020 | |
| Janssen Biotech, INC. | $163.20 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $141.47 | 2019-2021 | |
| Exelixis INC. | $132.97 | 2019-2022 | |
| Daiichi Sankyo INC. | $122.53 | 2020-2024 | Injectafer |
| Seagen INC. | $110.60 | 2020-2022 | |
| Emd Serono, INC. | $108.31 | 2019-2021 | |
| Incyte Corporation | $82.89 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.37 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.